BACKGROUND: Infection with the newly discovered human metapneumovirus (hMPV) may lead to hospitalization of children with lower respiratory tract infection (LRTI), although the pathogenesis thereof remains to be elucidated. METHODS: This hypothesis-generating study involved a cohort of children randomized to receive 9-valent conjugate pneumococcal vaccine or placebo and who were tested for hMPV infection when hospitalized for LRTI. By use of a nested reverse-transcription polymerase chain reaction assay targeted at amplifying a fragment of the hMPV fusion (F) protein gene, 202 such infections were identified among 2715 episodes of LRTI in children. RESULTS: Among human immunodeficiency virus (HIV)-uninfected children who had received 3 doses of conjugate pneumococcal vaccine, the incidence of hMPV-associated LRTI was reduced by 45% (95% confidence interval [CI], 19%-62%; P = .002), and the incidence of clinical pneumonia was reduced by 55% (95% CI, 22%-74%; P = .003). Similarly, in fully vaccinated HIV-infected children, the incidence of hMPV-associated LRTI was reduced by 53% (95% CI, 3%-77%; P = .035), and that of clinical pneumonia was reduced by 65% (95% CI, 19%-85%; P = .020). CONCLUSIONS: The pathogenesis of hMPV-associated LRTI that results in hospitalization of both HIV-infected and -uninfected children involves bacterial coinfection with pneumococcus, and a significant proportion of these hospitalizations may be prevented by vaccination with pneumococcal conjugate vaccine.
RCT Entities:
BACKGROUND:Infection with the newly discovered human metapneumovirus (hMPV) may lead to hospitalization of children with lower respiratory tract infection (LRTI), although the pathogenesis thereof remains to be elucidated. METHODS: This hypothesis-generating study involved a cohort of children randomized to receive 9-valent conjugate pneumococcal vaccine or placebo and who were tested for hMPVinfection when hospitalized for LRTI. By use of a nested reverse-transcription polymerase chain reaction assay targeted at amplifying a fragment of the hMPV fusion (F) protein gene, 202 such infections were identified among 2715 episodes of LRTI in children. RESULTS: Among human immunodeficiency virus (HIV)-uninfectedchildren who had received 3 doses of conjugate pneumococcal vaccine, the incidence of hMPV-associated LRTI was reduced by 45% (95% confidence interval [CI], 19%-62%; P = .002), and the incidence of clinical pneumonia was reduced by 55% (95% CI, 22%-74%; P = .003). Similarly, in fully vaccinated HIV-infectedchildren, the incidence of hMPV-associated LRTI was reduced by 53% (95% CI, 3%-77%; P = .035), and that of clinical pneumonia was reduced by 65% (95% CI, 19%-85%; P = .020). CONCLUSIONS: The pathogenesis of hMPV-associated LRTI that results in hospitalization of both HIV-infected and -uninfected children involves bacterial coinfection with pneumococcus, and a significant proportion of these hospitalizations may be prevented by vaccination with pneumococcal conjugate vaccine.
Authors: Krishna Pancham; Iman Sami; Geovanny F Perez; Shehlanoor Huseni; Bassem Kurdi; Mary C Rose; Carlos E Rodriguez-Martinez; Gustavo Nino Journal: Pediatr Neonatol Date: 2015-05-23 Impact factor: 2.083
Authors: Krishna Pancham; Geovanny F Perez; Shehlanoor Huseni; Amisha Jain; Bassem Kurdi; Carlos E Rodriguez-Martinez; Diego Preciado; Mary C Rose; Gustavo Nino Journal: Pediatr Res Date: 2015-06-18 Impact factor: 3.756
Authors: Carlos G Grijalva; Marie R Griffin; Kathryn M Edwards; John V Williams; Ana I Gil; Héctor Verastegui; Stella M Hartinger; Jorge E Vidal; Keith P Klugman; Claudio F Lanata Journal: Int J Epidemiol Date: 2013-06-14 Impact factor: 7.196
Authors: Irena Kukavica-Ibrulj; Marie-Eve Hamelin; Gregory A Prince; Constance Gagnon; Yves Bergeron; Michel G Bergeron; Guy Boivin Journal: J Virol Date: 2008-11-19 Impact factor: 5.103
Authors: Kevin C Yim; Rose P Cragin; Marina S Boukhvalova; Jorge C G Blanco; Marie-Eve Hamlin; Guy Boivin; David D Porter; Gregory A Prince Journal: Vaccine Date: 2007-05-15 Impact factor: 3.641